|
cMethDNA test Photo courtesy Johns Hopkins Kimmel Cancer Center
|
CANCER DIGEST – Feb. 5, 2017 – A blood test that spots cancer-linked DNA in women with advanced breast cancer correctly predicted that most of those patients with higher levels of the tumor markers died significantly earlier than those with lower levels.
The Johns Hopkins Kimmel Cancer Center scientists, who developed the test and led the study, say the results, if confirmed in more studies, suggest that the DNA detector, called cMethDNA, could be widely used to identify breast cancers at higher risk for recurrence and track the success or failure of treatment. Results of the study were published online Nov. 21, 2016 in the Journal of Clinical Oncology.